Wussow, Felix http://orcid.org/0000-0001-7624-6734
Kha, Mindy
Kim, Taehyun
Ly, Minh
Yll-Pico, Marcal http://orcid.org/0000-0002-7030-3360
Kar, Swagata
Lewis, Mark G. http://orcid.org/0000-0001-7852-0135
Chiuppesi, Flavia http://orcid.org/0000-0002-2921-5377
Diamond, Don J. http://orcid.org/0000-0003-3579-7083
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19 AI128913)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA111412, CA181045, CA107399)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 13 October 2022
Accepted: 28 February 2023
First Online: 16 March 2023
Competing interests
: While unknown whether publication of this report will aid in receiving grants and contracts, it is possible that this publication will be of benefit to City of Hope (COH). COH had no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript. D.J.D. and F.W. are co-inventors on patent application PCT/US2021/016247 which covers the design and construction of the synthetic MVA platform. D.J.D., F.W. and F.C. are co-inventors on PCT/US2021/032821 and provisional applications covering the development of ancestral and variant-adapted COVID-19 vaccines. D.J.D. is a consultant for GeoVax Labs Inc. All remaining authors declare no competing interests. GeoVax Labs Inc. has taken a worldwide exclusive license for COH04S1 from COH under the name of GEO-CM04S1.